AMPLIFY-7P
The randomised test of an off-the-shelf KRAS vaccine after pancreatic surgery. It missed its primary goal in June 2026.
Did not meet the pre-specified primary DFS endpoint in the intent-to-treat population; post-hoc landmark analyses suggested ~14% absolute DFS benefit during active dosing. Company is exploring R0-resected subgroups for phase 3. A cautionary data point for shared-antigen vaccines versus personalised approaches.
Pages like this
not linked directly; found by shared links- CompanyElicio Therapeutics
Shares ELI-002 7P, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- PersonElizabeth M. Jaffee
Shares Off-the-shelf cancer vaccines, Pancreatic ductal adenocarcinoma.
- IdeaOff-the-shelf KRAS vaccines after pancreatic cancer surgery
Shares Off-the-shelf cancer vaccines, The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeaA guaranteed purchase prize for the first drug against a named hard target
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductMRTX1133
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- IdeamRNA-delivered MYC decoy proteins instead of MYC inhibitors
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- InstitutionLaura and Isaac Perlmutter Cancer Center at NYU Langone Health
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.
- ProductElironrasib
Shares The undruggable drivers, Pancreatic ductal adenocarcinoma.